Etravirine: A Guide to Its Use in Treatment-Experienced Pediatric Patients with HIV-1 Infection in the US

被引：0
作者：
Katherine A. Lyseng-Williamson
机构：
[1] Adis,
来源：
Pediatric Drugs | 2012年 / 14卷 / 5期
关键词：
Virologic Response; Virologic Failure; Raltegravir; Maraviroc; Etravirine;
D O I：
10.1007/BF03262240
中图分类号：
学科分类号：
摘要：
Etravirine (Intelence®), an oral next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is approved for the treatment of HIV-1 infection in treatment-experienced patients. In the US, the approved use of etravirine in patients who have evidence of viral replication and harbor HIV-1 strains resistant to other antiretroviral agents has recently been expanded to include pediatric patients aged ≥6 to <18 years. At 24 and 48 weeks in an open-label trial, etravirine 5.2mg/kg twice daily (maximum dosage 200 mg twice daily) plus an optimized background therapy regimen achieved complete viral response (defined as HIV-1 RNA <50 copies/mL) in approximately half of treatment-experienced children and adolescents with HIV-1 infection and evidence of viral replication, and had an acceptable tolerability profile.
引用
收藏
页码：345 / 350
页数：5
相关论文
共 41 条
[1]  
Thompson M.A.(2012)Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel Ann Intern Med 156 817-33
[2]  
Mugavero M.J.(2006)Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience J Acquir Immune Defic Syndr 41 439-46
[3]  
Amico K.R.(2011)Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children Drugs 71 2131-49
[4]  
Shet A.(2012)Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection Drugs 72 847-69
[5]  
Berry L.(2007)Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 29-38
[6]  
Mohri H.(2007)Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 350 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 39-48
[7]  
Penazzato M.(2009)Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials AIDS 23 2289-300
[8]  
Giaquinto C.(2010)Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials Antiviral Ther 15 1045-52
[9]  
Croxtall J.D.(2006)Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol PLoS Pathog 2 e1 19-60
[10]  
Madruga J.V.(2004)Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants J Med Chem 47 2550-14
12345